Similar binding affinity to TFPI K1K2 (via K2) across human, cynomolgus monkey, rabbit, mouse and Wistar Han rat
“Marstacimab showed similar binding affinity to the combined K1K2 domains (via the K2 domain) of TFPI from human, cynomolgus monkey, rabbit, mouse, and the Wistar Han rat.”
Not conducted; weight-of-evidence assessment instead of 2-year rat study
“Based on the WoE provided by the Applicant, the Division agreed that marstacimab is unlikely to pose a significant carcinogenicity safety concern for humans and therefore considered a 2-year study in rats unlikely to provide additional useful information.”
No surrogate used; marstacimab binds TFPI of all test species
“Marstacimab showed similar binding affinity to the combined K1K2 domains (via the K2 domain) of TFPI from human, cynomolgus monkey, rabbit, mouse, and the Wistar Han rat.”